Save up -80% on Ertapenem
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Invanz
|price without discount in nearest pharmacy. Price may vary.|
We offer free Invanz coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Ertapenem every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Ertapenem volume of distribution
* 0.12 liter/kg (adults) * 0.2 liter/kg (pediatric, 3 months to 12 years) * 0.16 liter/kg (pediatric patients 13 to 17 years)
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Ertapenem
Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz reg;. It is structurally very similar to meropenem in that it possess a 1-beta-methyl group. (Wikipedia)
Ertapenem mechanism of action
The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In i Escherichia coli /i , it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3. Ertapenem is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. Ertapenem is hydrolyzed by metallo-beta-lactamases.
Dosage forms of Ertapenem
|Injection, powder, lyophilized, for solution||intramuscular; intravenous||1 g/1|
|Injection, powder, lyophilized, for solution||intravenous||1 g/1|
|Powder for concentrate for solution for infusion||Intravenous use||1 g|
(1R,5S,6S,8R,2’S,4’s)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid (4R,5S,6S)-3-((3S,5S)-5-((3-Carboxyphenyl)carbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo(3.2.0)hept-2-ene-2-carboxylic acid
Merck Sharp Dohme Corp.
Enteric bacteria and other eubacteria
Indication of Ertapenem
For the treatment the following moderate to severe infections caused by susceptible isolates of the designated microorganisms: (1) complicated intra-abdominal infections due to i Escherichia coli /i , i Clostridium clostridioforme /i , i Eubacterium lentum /i , i Peptostreptococcus /i species, i Bacteroides fragilis /i , i Bacteroides distasonis /i , i Bacteroides ovatus /i , i Bacteroides thetaiotaomicron /i , or i Bacteroides uniformis /i , (2) complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis due to i Staphylococcus aureus /i (methicillin susceptible isolates only), i Streptococcus agalactiae /i , i Streptococcus pyogenes /i , i Escherichia coli /i , i Klebsiella pneumoniae /i , i Proteus mirabilis /i , i Bacteroides fragilis /i , i Peptostreptococcus /i species, i Porphyromonas asaccharolytica /i , or i Prevotella bivia /i , (3) community acquired pneumonia due to i Streptococcus pneumoniae /i (penicillin susceptible isolates only) including cases with concurrent bacteremia, i Haemophilus influenzae /i (beta-lactamase negative isolates only), or i Moraxella catarrhalis /i , (4) complicated urinary tract infections including pyelonephritis due to i Escherichia coli /i , including cases with concurrent bacteremia, or i Klebsiella pneumoniae /i , (5) acute pelvic infections including postpartum endomyometritis, septic abortion and post surgical gynecologic infections due to i Streptococcus agalactiae /i , i Escherichia coli /i , i Bacteroides fragilis /i , i Porphyromonas asaccharolytica /i , i Peptostreptococcus /i species, or i Prevotella bivia /i .
Toxicity of Ertapenem
No specific information is available on the treatment of overdosage with ertapenem. Intentional overdosing of ertapenem is unlikely. Intravenous administration of ertapenem at a dose of 2 g over 30 min or 3 g over 1-2 hr in healthy adult volunteers resulted in an increased incidence of nausea. In clinical trials in adults, inadvertent administration of three 1 g doses of ertapenem in a 24 hour period resulted in diarrhea and transient dizziness in one patient. In pediatric clinical trials, a single intravenous dose of 40 mg/kg up to a maximum of 2 g did not result in toxicity.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Ertapenem on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.